Physician profile
Kesheng Wu
NPI 1932119385
$2,050.46
in general payments reported to CMS, 2019-2025
19 companies · $99.91 in 2025
The $99.91 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $144 · 2021: $462 · 2022: $422 · 2023: $334 · 2024: $231 · 2025: $99.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569 · Education: $95.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $569.07 |
| Education | $95.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $532.64 | 2019-2023 | Myrbetriq, Veozah |
| Amgen INC. | $339.20 | 2019-2025 | Evenity, Repatha, Repatha |
| Glaxosmithkline, LLC. | $224.85 | 2019-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $192.79 | 2019-2025 | Verquvo, Belsomra |
| Almatica Pharma LLC | $87.14 | 2021-2023 | Loreev Xr |
| Smith+Nephew, INC. | $82.01 | 2019-2025 | Collagenase Santyl |
| E.R. Squibb & Sons, L.L.C. | $71.77 | 2022-2023 | Eliquis |
| Lilly USA, LLC | $71.64 | 2019-2021 | |
| Allergan, INC. | $66.34 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.15 | 2019-2024 | |
| Amarin Pharma, INC. | $57.50 | 2021 | |
| Abbvie INC. | $48.40 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $40.75 | 2019-2025 | Breztri |
| Sunovion Pharmaceuticals INC. | $40.56 | 2019-2020 | |
| Ucb, INC. | $39.28 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27.48 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.03 | 2022 | |
| Scilex Pharmaceuticals INC. | $22.25 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.68 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kesheng Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.